ROBESONIA, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Blaqclouds, Inc. (OTC: BCDS), a leading Web3 infrastructure and decentralized finance company, today announced it has entered into a Blockchain & Development Partnership Agreement with Super Studios USA, an emerging powerhouse in film, television, and mixed-use real estate development. Under the terms of the agreement, Super Studios USA has funded the hard costs associated with the blockchain development of their project and ...

OTTAWA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, has scheduled a conference call on Tuesday, November 4, 2025, at 10:30 a.m. EST to discuss its financial results for the three and nine month periods ended September 30, 2025. Prior to the commencement of the call, Telesat will post a news release containing its financial results on its website (www.telesat.com) under the tab “Investors” and ...

Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into two additional minority stake strategic investments, including an ...

CORNELIUS, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD) today announced the appointment of Puneet “Pete” Vij as Vice President of Technology, where he will oversee the company’s national rollout of AlphaCash, its proprietary network of next-generation financial service kiosks. The rollout will be managed under Alpha Modus Financial Services, a newly formed subsidiary of Alpha Modus Holdings dedicated to advancing financial inclusion through ...

LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against LifeMD, Inc. (“LifeMD” or “the Company”) (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...

SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Sound Group Inc. (“Sound Group” or the “Company”) (NASDAQ: SOGP), a global AI-powered audio company, today announced that one of its subsidiaries has officially donated to establish the "HKUST(GZ) Information Hub - LIZHI Innovation Talent Scholarship" (the "LIZHI Innovation Talent Scholarship") at The Hong Kong University of Science and Technology (Guangzhou). The scholarship will provide recipients with opportunities to participate in ...

SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Netflix, Inc. (NASDAQ: NFLX). If you have information that could assist in the Netflix investigation or if you are a Netflix investor who suffered a loss and would like to learn more, you can provide your information here: You can also ...

ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the promotion of Dr. Xiaoli Zhang to the position of Chief Scientist. This promotion follows a series of groundbreaking scientific achievements under Dr. Zhang's leadership that are laying the foundation for the next generation of spider silk-based super materials. Dr. Zhang joined Kraig Labs in ...

- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced ...

LAS VEGAS, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcadia® (arcadia.io), a leading healthcare data platform, today announced the successful conclusion of Aggregate 2025, its annual customer conference. With 200+ attendees representing more than 50 organizations and a dozen partners, the three-day event featured intensive training, workflow consulting, peer knowledge exchange, real-world examples of innovation in action, and an immersive AI Showcase demonstrating how data and artificial ...

PORT ANGELES, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- First Northwest Bancorp (Nasdaq: FNWB) ("First Northwest" or the "Company"), the holding company for First Fed Bank ("First Fed" or the "Bank"), today reported net income of $802,000 for the third quarter of 2025, compared to net income of $3.7 million for the second quarter of 2025 and a net loss of $2.0 million for the third quarter of 2024. Basic and diluted income per share were $0.09 for the third quarter of 2025, compared ...

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share. The gross proceeds to Nurix from the ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia CHATHAM, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p<0.0001), and improvements were sustained at 12 months (p<0.0001) in BBP-418 treated individuals versus placebo - Average reduction in serum CK, a marker of muscle damage, of ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal studyPreliminary efficacy data demonstrate achievement of definition of remission in SLE (DORIS) in 83% of patients and complete renal response (CRR) in 50% of patients; all responses and remissions are ongoing with no evidence of disease activity at a median follow-up of ...

TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) has launched a new program to advance mineral deposit modelling and feedstock integration at its Iron Creek cobalt-copper project in Idaho, supporting U.S. efforts to onshore critical mineral production and reduce dependence on foreign supply chains. With financing for its North American cobalt refinery now completed and construction scheduled to ...

New York, NY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Chijet Motor Company, Inc. (NASDAQ: CJET) (“Chijet” or the “Company”) today announced the successful closing of a private placement offering of units, consisting of ordinary shares and warrants, for gross proceeds equivalent to $300 million in cryptocurrency. The offering was conducted with select non-U.S. institutional investors. Each unit comprises one ordinary share (par value $0.003) priced at the equivalent of $0.10 per share in ...

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment ...

EDAP to Participate in the UBS Global Healthcare Conference Company to Host 1x1 Investor Meetings on Monday, November 10th, 2025 AUSTIN, Texas, October 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer, are scheduled to host 1x1 investor meetings at the upcoming UBS Global Healthcare Conference, which is being held November ...

Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across ...